Cannell & Co. Has $266,000 Stock Holdings in Surgery Partners, Inc. (NASDAQ:SGRY)

Cannell & Co. lowered its stake in shares of Surgery Partners, Inc. (NASDAQ:SGRY - Free Report) by 90.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,300 shares of the company's stock after selling 76,670 shares during the period. Cannell & Co.'s holdings in Surgery Partners were worth $266,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Sivik Global Healthcare LLC boosted its stake in Surgery Partners by 14.3% during the fourth quarter. Sivik Global Healthcare LLC now owns 200,000 shares of the company's stock worth $6,398,000 after buying an additional 25,000 shares during the period. Headlands Technologies LLC purchased a new stake in Surgery Partners in the fourth quarter valued at approximately $145,000. State of New Jersey Common Pension Fund D boosted its position in shares of Surgery Partners by 13.2% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 78,130 shares of the company's stock worth $2,499,000 after buying an additional 9,114 shares during the period. New York State Common Retirement Fund grew its stake in shares of Surgery Partners by 12.7% in the fourth quarter. New York State Common Retirement Fund now owns 30,679 shares of the company's stock valued at $981,000 after buying an additional 3,468 shares in the last quarter. Finally, Handelsbanken Fonder AB raised its holdings in shares of Surgery Partners by 43.0% in the 4th quarter. Handelsbanken Fonder AB now owns 11,300 shares of the company's stock valued at $361,000 after buying an additional 3,400 shares during the period.

Surgery Partners Stock Down 1.9 %

SGRY stock traded down $0.47 during trading on Friday, hitting $24.53. 887,364 shares of the company's stock were exchanged, compared to its average volume of 887,843. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.71 and a quick ratio of 1.57. Surgery Partners, Inc. has a 52-week low of $22.05 and a 52-week high of $45.79. The business has a 50-day moving average price of $27.80 and a two-hundred day moving average price of $29.72.

Surgery Partners (NASDAQ:SGRY - Get Free Report) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.37 by $0.07. The firm had revenue of $735.40 million for the quarter, compared to analyst estimates of $741.93 million. Surgery Partners had a negative net margin of 0.43% and a positive return on equity of 3.65%. Surgery Partners's revenue for the quarter was up 4.0% compared to the same quarter last year. During the same period last year, the business earned $0.22 EPS. As a group, equities research analysts expect that Surgery Partners, Inc. will post 0.78 EPS for the current fiscal year.

Insider Buying and Selling at Surgery Partners

In other Surgery Partners news, insider Bradley R. Owens sold 1,040 shares of the firm's stock in a transaction on Monday, February 12th. The stock was sold at an average price of $35.22, for a total value of $36,628.80. Following the completion of the sale, the insider now owns 73,149 shares of the company's stock, valued at $2,576,307.78. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, insider Bradley R. Owens sold 1,040 shares of the company's stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $35.22, for a total value of $36,628.80. Following the sale, the insider now owns 73,149 shares in the company, valued at approximately $2,576,307.78. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Jason Eric Evans sold 5,780 shares of the business's stock in a transaction on Monday, February 12th. The stock was sold at an average price of $35.08, for a total value of $202,762.40. Following the sale, the chief executive officer now owns 419,118 shares in the company, valued at $14,702,659.44. The disclosure for this sale can be found here. Over the last three months, insiders have sold 14,831 shares of company stock worth $482,609. 2.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on SGRY shares. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $49.00 target price on shares of Surgery Partners in a research report on Thursday, February 29th. Cantor Fitzgerald reiterated an "overweight" rating and set a $43.00 target price on shares of Surgery Partners in a report on Wednesday, April 10th. StockNews.com raised Surgery Partners from a "sell" rating to a "hold" rating in a research report on Thursday, March 21st. Benchmark reiterated a "buy" rating and issued a $50.00 target price on shares of Surgery Partners in a report on Wednesday. Finally, Citigroup cut their price target on Surgery Partners from $43.00 to $42.00 and set a "buy" rating on the stock in a report on Tuesday, February 27th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, Surgery Partners currently has an average rating of "Moderate Buy" and an average price target of $43.63.

About Surgery Partners

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.